AFFiRiS AG

Founded

2003

Staff

61

Organization type

RDM biotech/pharma

Region

Vienna

AFFiRiS develops first-in-class specific active immunotherapies (SAIT) for the prevention and treatment of chronic illnesses. SAIT candidates are based on a flexible modular system consisting of peptides conjugated to carrier proteins and an adjuvant. Our proprietary AFFITOME®-Technology delivers peptides that are close variants of a target specific epitope and are optimized for immunogenicity, thereby inducing an antibody response that is cross-reactive to the original target.

R&D:Our clinical stage projects focus on Atherosclerosis prevention targeting PCSK9 and Parkinson’s disease targeting α synuclein. Our pre-clinical projects focus on Huntington's targeting mutHTT and other undisclosed targets.